NASDAQ:PNT - POINT Biopharma Global Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.50
  • Forecasted Upside: 45.52 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$8.59
▼ -0.34 (-3.81%)

This chart shows the closing price for PNT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New POINT Biopharma Global Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PNT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PNT

Analyst Price Target is $12.50
▲ +45.52% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for POINT Biopharma Global in the last 3 months. The average price target is $12.50, with a high forecast of $17.00 and a low forecast of $8.00. The average price target represents a 45.52% upside from the last price of $8.59.

This chart shows the closing price for PNT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in POINT Biopharma Global.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/31/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/29/2021CowenInitiated CoverageOutperformHigh
7/27/2021Jefferies Financial GroupInitiated CoverageHold$8.00Low
7/26/2021Piper SandlerInitiated CoverageOverweight$17.00Medium
(Data available from 9/27/2016 forward)

News Sentiment Rating

0.29 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/28/2021
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/27/2021

Current Sentiment

  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
POINT Biopharma Global logo
POINT Biopharma Global Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of radioligand therapies for the treatment of cancer. Its products include PNT2001, a PSMA radioligand that is in preclinical studies for early stage prostate cancer treatment; PNT2002, which is in Phase 3 studies to evaluate superiority to the standard of care in mCRPC patients; PNT2003, a somatostatin-targeted radioligand therapy that is in Phase 3 trials for the treatment of patients with somatostatin receptor-positive neuroendocrine tumors; and PNT2004, a radioligand that targets fibroblast activation protein-a. The company is based in Indianapolis, Indiana.
Read More

Today's Range

Now: $8.59
Low: $8.58
High: $8.96

50 Day Range

MA: $9.34
Low: $7.67
High: $11.26

52 Week Range

Now: $8.59
Low: $7.65
High: $18.08

Volume

40,800 shs

Average Volume

124,535 shs

Market Capitalization

$774.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of POINT Biopharma Global?

The following Wall Street analysts have issued research reports on POINT Biopharma Global in the last twelve months: Cowen Inc, Jefferies Financial Group Inc., and Piper Sandler.
View the latest analyst ratings for PNT.

What is the current price target for POINT Biopharma Global?

2 Wall Street analysts have set twelve-month price targets for POINT Biopharma Global in the last year. Their average twelve-month price target is $12.50, suggesting a possible upside of 45.5%. Piper Sandler has the highest price target set, predicting PNT will reach $17.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $8.00 for POINT Biopharma Global in the next year.
View the latest price targets for PNT.

What is the current consensus analyst rating for POINT Biopharma Global?

POINT Biopharma Global currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PNT will outperform the market and that investors should add to their positions of POINT Biopharma Global.
View the latest ratings for PNT.

How do I contact POINT Biopharma Global's investor relations team?

POINT Biopharma Global's physical mailing address is 200 BERKELEY STREET 18TH FLOOR, BOSTON MA, 02116. The company's listed phone number is 64-7812-2417. The official website for POINT Biopharma Global is www.pointbiopharma.com.